Interpreting Plasma Estrogen Levels in Breast Cancer: Caution Needed
Authors:
- 10 May 2014
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (14) , 1396-1400
Abstract
No abstract availableThis publication has 54 references indexed in Scilit:
- Comparisons of Immunoassay and Mass Spectrometry Measurements of Serum Estradiol Levels and Their Influence on Clinical Association Studies in MenThe Journal of Clinical Endocrinology & Metabolism, 2013
- The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancerAnnals of Oncology, 2013
- Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patientsSpringerPlus, 2013
- Whole-genome analysis informs breast cancer response to aromatase inhibitionNature, 2012
- Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor ModulatorJournal of Oncology Practice, 2012
- Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling ProjectBreast Cancer Research and Treatment, 2011
- Analysis of estrogens in serum and plasma from postmenopausal women: Past present, and futureSteroids, 2010
- Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal WomenJournal of Clinical Oncology, 2010
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast CancerBreast Cancer Research and Treatment, 2006